Note 14 - Merger - Summary of Estimated Purchase Consideration (Details) - Viewpoint Molecular Targeting, Inc. [Member] $ in Thousands |
Feb. 03, 2023
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Perspective Therapeutics common stock issued (13,654,507 x $4.00) | $ 54,618 |
Assumption of Viewpoint stock options and warrants at fair value | 7,836 |
Note receivable and interest from Viewpoint forgiven | 6,171 |
Total fair value of consideration transferred | $ 68,625 |
X | ||||||||||
- Definition Amount of liabilities forgiven by the acquirer as part of consideration transferred in a business combination. No definition available.
|
X | ||||||||||
- Definition The amount of fair value of options and warrants assumed in business acquisition. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|